Glycoantigen 242 is high at 42.4 kU/L. It is recommended to retest and improve imaging and other related tests. In addition, it should also follow the doctor’s instructions for regular review and observation of indicator changes. Glycoantigen 242 is a tumor-associated glycocalyx antigen, and its elevation is mainly seen in pancreatic cancer, with a sensitivity slightly lower than that of CA19-9, but CA242 is seldom elevated in benign diseases. It is currently used as a clinical tumor screening marker, with a normal reference value of less than 20 kU/L. Elevated levels can be seen in pancreatic, colon, and gastric cancers, as well as ovarian, uterine, and lung cancers, and in non-malignant tumors. Since Glycoantigen 242 does not have the ability to be used independently for cancer diagnosis, when its level is elevated, it is necessary to choose CT or other imaging diagnosis on the basis of retesting, combined with pathologic examination to clarify the condition. It is recommended that patients should not be too nervous, and should consult a doctor in time for standardized diagnosis and treatment.